Ų…ŲŠŲ…ŲžØ§ØąØ§

Country: āĻ‡āĻ¸ā§āĻ°āĻžāĻ¯āĻŧā§‡āĻ˛

āĻ­āĻžāĻˇāĻž: āĻ†āĻ°āĻŦā§€

āĻ¸ā§‚āĻ¤ā§āĻ°: Ministry of Health

āĻāĻ–āĻ¨ āĻāĻŸāĻž āĻ•āĻŋāĻ¨ā§āĻ¨

āĻ¸āĻ•ā§āĻ°āĻŋāĻ¯āĻŧ āĻ‰āĻĒāĻžāĻĻāĻžāĻ¨:

CINACALCET HYDROCHLORIDE 90 MG

āĻĨā§‡āĻ•ā§‡ āĻĒāĻžāĻ“āĻ¯āĻŧāĻž:

AMGEN EUROPE B.V.

āĻāĻŸāĻŋāĻ¸āĻŋ āĻ•ā§‹āĻĄ:

H05BX01

āĻĢāĻžāĻ°ā§āĻŽāĻžāĻ¸āĻŋāĻ‰āĻŸāĻŋāĻ•āĻžāĻ˛ āĻĢāĻ°ā§āĻŽ:

FILM COATED TABLETS

āĻĒā§āĻ°āĻļāĻžāĻ¸āĻ¨ āĻ°ā§āĻŸ:

PER OS

Manufactured by:

AMGEN EUROPE B.V., NETHERLANDS

Therapeutic group:

CINACALCET

āĻĨā§‡āĻ°āĻžāĻĒāĻŋāĻ‰āĻŸāĻŋāĻ• āĻ‡āĻ™ā§āĻ—āĻŋāĻ¤:

Treatment of secondary hyperparathyrodism (HPT) in patients with end-dtage renal disease (ESRD) on maintenance dialysis therapy. Mimpara may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols as appropriate. Reduction of hypercalcaemia in patients with parathyroid carcinoma.

āĻ…āĻ¨ā§āĻŽā§‹āĻĻāĻ¨ āĻ¤āĻžāĻ°āĻŋāĻ–:

2012-10-01

āĻāĻ‡ āĻĒāĻŖā§āĻ¯ āĻ¸āĻŽā§āĻĒāĻ°ā§āĻ•āĻŋāĻ¤ āĻ¸āĻ¤āĻ°ā§āĻ•āĻ¤āĻž āĻ…āĻ¨ā§āĻ¸āĻ¨ā§āĻ§āĻžāĻ¨ āĻ•āĻ°ā§āĻ¨

āĻĻāĻ¸ā§āĻ¤āĻžāĻŦā§‡āĻœ āĻ‡āĻ¤āĻŋāĻšāĻžāĻ¸ āĻĻā§‡āĻ–ā§āĻ¨